Curanex Pharmaceuticals Inc

Listed Company

CURXCIK 0002025942NasdaqEmerging GrowthPharmaceutical PreparationsNevadaFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-4.23M

Total Assets

$11.58M

Equity

$11.22M

Shares Out

28.36M

Op. Cash Flow

$-10.48M

Business

Curanex Pharmaceuticals Inc is a publicly listed company in Pharmaceutical Preparations, incorporated in Nevada. Common stock trades on Nasdaq under the ticker CURX.

Auto-generated from company profile

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31
General & Administrative	1	290,386
IP Development Impairments	—	74,676
Research & Development	3	—
Total Operating Expenses	4	365,062
Loss from Operations	−4	−365,062
Interest Expense	−8,537	—
Other Income	22,507	3,556
Net Loss	−4	−361,506
Net loss per common share: Basic	−0.17	−0.03
Net loss per common share: Diluted	−0.17	−0.03
Weighted average number of common shares outstanding: Basic	25	13
Weighted average number of common shares outstanding: Diluted	25	13

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Cash	5	148,891	—
Prepaid Expenses	6	1,179	—
Other Current Assets	—	367,865	—
Total Current Assets	11	517,935	—
Right-of-Use Asset	352,616	—	—
TOTAL ASSETS	12	517,935	—
Accrued Expenses	11,915	9,575	—
Accounts Payable	2,426	5,000	—
Lease Liability, Current	122,689	—	—
Total Current Liabilities	137,030	14,575	—
Lease Liability, Noncurrent	224,010	—	—
TOTAL LIABILITIES	361,040	14,575	—
Common Stock, 475,000,000 Shares Authorized; $0.0001 par Value; 28,340,812 Shares Issued and Outstanding as of December 31, 2025, and 24,000,000 December 31, 2024	2,834	2,400	—
Preferred Stock, 25,000,000 Shares Authorized; $0.0001 par Value; 1,000,000 Shares Issued and Outstanding as of December 31, 2025, and December 31, 2024	100	100	—
Common Stock to be Issued	—	200,000	—
Additional Paid-in Capital	16	923,309	—
Accumulated Deficit	−5	−622,449	—
TOTAL SHAREHOLDERS EQUITY	11	503,360	60,090
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	12	517,935	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31
Amortization of Right-of-Use Assets	79,396	—
IP Development Impairments	—	74,676
Prepaid Expenses	−6	−1,179
Lease Liabilities	−85,210	—
Accounts Payable	−2,574	5,000
Accrued Expenses	2,340	−4,701
Other Current Assets	—	−267,865
NET CASH USED IN OPERATING ACTIVITIES	−10	−555,575
Issuance of Common Stock Private Placements	—	630,000
Issuance of Preferred Stock	—	100
Proceeds from Issuance of Common Stock, net of Underwriting Costs - IPO	16	—
Payment of Offering Costs	−346,497	—
NET CASH PROVIDED BY FINANCING ACTIVITIES	15	630,100
NET INCREASE IN CASH	5	74,525
Issuance of Common Stock with Non-cash Payment	—	100,000
Recognition of Right-of-Use Asset in Exchange for Lease Liability	323,820	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro